Heart Failure With Reduced Ejection Fraction: Clinical Trials

84 completed, 51 unknown, 43 recruiting, 12 not yet recruiting. 91 Not applicable, 25 Phase 4, 20 Phase 2, 13 Phase 1, 12 Phase 3.

By phase and status

Phase	Trials	Status
Not applicable	91	Completed 28, Unknown 23, Recruiting 22, Not yet recruiting 6, Terminated 5, Active not recruiting 4, Withdrawn 3
Phase 4	25	Unknown 8, Completed 7, Recruiting 4, Terminated 3, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1
Phase 2	20	Completed 10, Recruiting 5, Unknown 3, Active not recruiting 1, Terminated 1
Phase 1	13	Completed 7, Recruiting 2, Active not recruiting 1, Enrolling by invitation 1, Not yet recruiting 1, Unknown 1
Phase 3	12	Recruiting 5, Completed 2, Terminated 2, Active not recruiting 1, Not yet recruiting 1, Unknown 1
Early Phase 1	2	Completed 1, Recruiting 1

Follow Heart Failure With Reduced Ejection Fraction: new trials by email Literature Review of Heart Failure With Reduced Ejection Fraction trials Research Report on Heart Failure With Reduced Ejection Fraction

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
PCI With GDMT Versus GDMT Alone for Patients With Ischemic Cardiomyopathy and Reduced LVEF Percutaneous coronary intervention, Guideline-directed medical therapy - Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease	Not applicable	Not yet recruiting	Nanjing First Hospital, Nanjing Medical University	1154	2026-12-30	2026-05-28
Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score Metoprolol Succinate, Beta-Blocker Polygenic Score, Illumina Infinium Global Diversity Array with Enhanced Pharmacogenomics (PGx) - Heart Failure With Reduced Ejection Fraction	Phase 4	Recruiting	University of Michigan	100	2026-12-01	2026-10-15
Optimal PharmacoTherapy and Invasive Management of Atrial Fibrillation in Patients With Heart Failure Pulmonary Vein Isolation, Pharmacological Rate Control - Heart Failure With Reduced Ejection Fraction, Atrial Fibrillation (AF)	Phase 3	Not yet recruiting	University of British Columbia	1050	2026-11-01	2026-10-14
Metabolic Changes in Heart Failure Patients Treated With Vericiguat Vericiguat - Heart Failure, Worsening Heart Failure		Not yet recruiting	University of Salerno	30	2026-11-01	2026-10-29
[11C]PS13 PET Imaging of Neuroinflammation in Heart Failure With Reduced Ejection Fraction [11C]PS13: [carbon-11]PS13; COX-1 PET radioligand, Sacubitril-Valsartan - Heart Failure With Reduced Ejection Fraction, Cognitive Impairment, Mild	Phase 1	Not yet recruiting	Stony Brook University	18	2026-10-01	2026-10-02
Utilization of Guided Point of Care Ultrasound in Heart Failure Diagnosis Pilot Trial Point of Care Ultrasound - Heart Failure With Reduced Ejection Fraction	Not applicable	Not yet recruiting	Corewell Health West	100	2026-09-30	2026-09-18
Intermediate Outcomes of HFrEF Patients on Guideline-Directed Medical Therapy Heart Failure With Reduced Ejection Fraction, HFrEF - Heart Failure With Reduced Ejection Fraction		Not yet recruiting	Assiut University	250	2026-09-26	2026-09-30
A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease Pulmonary Artery Denervation (PADN), Sham procedure control - Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction	Not applicable	Recruiting	Pulnovo Medical, Inc.	750	2026-08-21	2026-10-20
HFrEF Polypill in Sri Lanka RCT Usual Care, HFrEF Polypill - Heart Failure With Reduced Ejection Fraction	Phase 3	Recruiting	Washington University School of Medicine	1672	2026-08-17	2026-10-22
STEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart Failure Stepwise Withdrawal of ARNI and SGLT2i, Continued Guideline-Directed Medical Therapy - Heart Failure With Reduced Ejection Fraction, Heart Failure	Phase 4	Recruiting	Kyungsub Song	80	2026-08-12	2026-09-02
Midodrine in Heart Failure With Reduced Ejection Fraction With Hypotension Midodrine Oral Tablet - Heart Failure With Reduced Ejection Fraction, Hypotension	Phase 2 / Phase 3	Recruiting	Ottawa Heart Institute Research Corporation	56	2026-08-07	2026-09-08
Synchronized Diaphragmatic Stimulation in Symptomatic Heart Failure Synchronized Diaphragmatic Stimulation - Heart Failure With Reduced Ejection Fraction	Not applicable	Recruiting	VisCardia Inc.	270	2026-07-08	2026-10-23
STRATegy SUccesS in High-Risk PCI With Impella CP: Evaluation of Hemodynamic Protection in Complex PCI Impella CP - Coronary Artery Disease, Heart Failure With Reduced Ejection Fraction	Not applicable	Not yet recruiting	Rayyan Hemetsberger	50	2026-07-01	2026-05-27
Lumacaftor Yields Reversal of Impaired Cerebral Blood Flow in Heart Failure Patients Lumacaftor 200 MG, Placebo - Heart Failure With Reduced Ejection Fraction	Phase 2	Recruiting	Qanatpharma AG	60	2026-07-01	2026-07-17
A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction HJB647 low dose, HJB647 high dose, Placebo - Heart Failure With Reduced Ejection Fraction	Phase 1	Recruiting	Novartis Pharmaceuticals	12	2026-03-18	2026-10-01
Circulating RNA Markers of Ventricular Arrhythmias in Remotely Monitored Patients With Post-Infarction Heart Failure and Implanted Cardioverter-Defibrillators Circulating Small RNA Profiling - Heart Failure With Reduced Ejection Fraction, Ventricular Arrhythmia		Active not recruiting	University of Rzeszow	57	2026-03-12	2026-08-31
Digital Remote Management Versus Usual Care for Optimization of Guideline-directed Medical Therapy in Patients With Heart Failure and Reduced Ejection Fraction: a Multicentre, Randomised, Controlled Trial (DigiCare-HFrEF) Digital Remote Management - Heart Failure With Reduced Ejection Fraction	Not applicable	Recruiting	Beijing Anzhen Hospital	252	2026-02-26	2026-04-24
A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan Heart Failure With Reduced Ejection Fraction		Completed	Novartis Pharmaceuticals	2508	2026-01-28	2026-07-06
High Fat Diet for Cardiac Metabolic Reprogramming High fat diet, Standard diet - Non-ischemic Dilated Cardiomyopathy, Heart Failure With Reduced Ejection Fraction	Not applicable	Recruiting	Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III	80	2026-01-15	2026-05-26
Digital Support Program for Patients With Heart Failure - a Cluster-Randomized Hybrid Type 2 Study Tailored implementation support - Heart Failure With Reduced Ejection Fraction	Not applicable	Recruiting	Linkoeping University	240	2025-12-15	2026-02-27

Showing 20 of 223. Sign in to see all of them.

Narrower conditions

Heart Failure (98)  ·  Heart Failure, Systolic (9)  ·  Atrial Fibrillation (8)  ·  Cardiovascular Diseases (8)  ·  Hypertension, Pulmonary (7)  ·  Coronary Artery Disease (6)  ·  Arrhythmias, Cardiac (4)  ·  Bundle-Branch Block (4)  ·  Heart Diseases (4)  ·  Heart Failure, Diastolic (4)  ·  Hyperkalemia (4)  ·  Iron Deficiencies (4)  ·  Ketosis (4)  ·  Motor Activity (4)  ·  Ventricular Dysfunction, Left (4)

Broader conditions

Cardiovascular Diseases (121)  ·  Heart Diseases (121)  ·  Pathological Conditions, Signs and Symptoms (39)  ·  Pathologic Processes (33)  ·  Nutritional and Metabolic Diseases (22)  ·  Arrhythmias, Cardiac (17)  ·  Metabolic Diseases (17)  ·  Vascular Diseases (15)  ·  Behavior (9)  ·  Cardiac Conduction System Disease (9)  ·  Myocardial Ischemia (9)  ·  Respiratory Tract Diseases (9)  ·  Lung Diseases (8)  ·  Urogenital Diseases (8)  ·  Female Urogenital Diseases (7)

Interventions

sacubitril and valsartan sodium hydrate drug combination (11)  ·  empagliflozin (7)  ·  Echocardiography (3)  ·  Exercise (3)  ·  Sodium-Glucose Transporter 2 Inhibitors (3)  ·  Spironolactone (3)  ·  dapagliflozin (3)  ·  omecamtiv mecarbil (3)  ·  BID protein, human (2)  ·  Bisoprolol (2)  ·  Cardiac Resynchronization Therapy (2)  ·  Educational Status (2)  ·  Enalapril (2)  ·  Exercise Test (2)  ·  Iron (2)

Sponsors

Novartis Pharmaceuticals (5)  ·  Yale University (4)  ·  Cytokinetics (3)  ·  Duke University (3)  ·  NYU Langone Health (3)  ·  University of Virginia (3)  ·  Alexandria University (2)  ·  Assiut University (2)  ·  Brigham and Women's Hospital (2)  ·  Bristol-Myers Squibb (2)  ·  Cairo University (2)  ·  Cardurion Pharmaceuticals, Inc. (2)  ·  Chongqing Medical University (2)  ·  Copenhagen University Hospital, Rigshospitalet (2)  ·  Linkoeping University (2)

Countries

United States (73)  ·  Canada (20)  ·  United Kingdom (19)  ·  Italy (18)  ·  China (16)  ·  Germany (13)  ·  Spain (13)  ·  France (11)  ·  Netherlands (11)  ·  Poland (11)  ·  Sweden (9)  ·  Belgium (8)  ·  Denmark (8)  ·  South Korea (8)  ·  Egypt (6)

Top investigators

Amrita Mukhopadhyay, MD (2)  ·  Francis P Wilson, MD MSCE (2)  ·  John Boehmer, MD (2)  ·  Nir Uriel, MD (2)  ·  Tariq Ahmad, MD MPH (2)  ·  A. Pandey, MD (1)  ·  Adam DeVore, MD (1)  ·  Adrian Soto, Ph.D, MD. (1)  ·  Albert Hagege, MD, PhD (1)  ·  Alexander Postalian, MD (1)  ·  Anastasia Shchendrygina (1)  ·  Andreas Gevaert (1)  ·  Andrew S Flett, MBBS BSc MD (1)

Results publications

PMID 32222134, PMID 34447992, PMID 15860469, PMID 15963399, PMID 17684064, PMID 18684274, PMID 20607462, PMID 21300176, PMID 21440872, PMID 21885793, PMID 22980301, PMID 23563576, PMID 24658015, PMID 25176015, PMID 25399909, PMID 25403646, PMID 25416329, PMID 26022006, PMID 26231885, PMID 26240596, PMID 26280447, PMID 26541915, PMID 26746456, PMID 26754626, PMID 26915374, PMID 27130705, PMID 27143684, PMID 27170530, PMID 27179829, PMID 27296397, PMID 27354044, PMID 27395349, PMID 27618854, PMID 27842179, PMID 27895026, PMID 27908347, PMID 27940967, PMID 28705910, PMID 28784687, PMID 29018174, PMID 29141857, PMID 29164797, PMID 29239515, PMID 29433525, PMID 29617523, PMID 29661699, PMID 29748349, PMID 30204280, PMID 30258648, PMID 30415602

NIH funding

2023 (3), 2017 (2), 2018 (2), K23HL161348 (2), 1UG3HL163311-01A1 (1), 2009 (1), 2015 (1), F32HL143916 (1), K23HL127099 (1), K23HL177311 (1), R01AG075556 (1), R01DK107680 (1), R01HL172830 (1), R01HL176491 (1), R01HL178410 (1)